Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Asthma I: Introduction

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...

Asthma III: Clinical Manifestations

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Antiasthma Drugs: β2-Adrenoceptor Agonists

Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Methyltransferase 3 promotes v-set and transmembrane domain-containing 2-like protein expression to intensify ferroptosis-mediated prostate adenocarcinoma progression through the m6A methylation modification.

Histology and histopathology·2026

Same author

Robo2-Nrxn3 Deficiency: A Molecular Hub Linking Excitation-Inhibition Imbalance to the Pathogenesis of Schizophrenia.

Schizophrenia bulletin·2026

Same author

A CHKA-PML autophagy checkpoint enables tumors to evade glutamine starvation.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Global research trends and hotspots in breast cancer related fatigue: a bibliometric investigation.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Same author

Glutamine Deprivation Triggers Tribbles Homolog 3 Dependent G-Quadruplex Resolution to Maintain DNA Repair and Tumor Survival.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

DCAF13 Safeguards Hematopoietic Stem Cells via RRS1-Regulated Ribosome Biogenesis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Search research articles

Related Experiment Video

Updated: May 21, 2026

Murine Model of Allergen Induced Asthma

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

TH17 functional study in severe asthma using agent based model.

Liyan Song¹, Yunbo Guo, Qingkai Deng

¹Department of Bioinformatics, School of Basical Medical Sciences, Southern Medical University, China.

Journal of Theoretical Biology

|June 5, 2012

Summary

This summary is machine-generated.

Severe asthma involves increased T helper 17 (TH17) cells, driven by the DC-IL23-TH17 axis. This simulation supports TH17 as a potential therapeutic target for severe asthma treatment.

More Related Videos

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

Related Experiment Videos

Last Updated: May 21, 2026

Murine Model of Allergen Induced Asthma

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

Area of Science:

Immunology
Computational Biology
Respiratory Medicine

Background:

T helper 17 (TH17) cells, a CD4+ T cell subset, are elevated in severe asthma patients compared to common asthma.
TH17 cells, regulated by IL23, produce IL17A and IL17F, contributing to severe asthma pathogenesis by affecting epithelial cells.
The precise role of TH17 cells in driving neutrophilic inflammation in severe asthma requires further investigation.

Purpose of the Study:

To explore the function of TH17 cells in severe asthma.
To model the complex interactions within the immune system involving TH17 cells.
To identify potential therapeutic targets for severe asthma.

Main Methods:

Utilized the Basic Immune Simulator (BIS) platform to create and simulate TH17 models.
Compared TH17 models with Dendritic Cell (DC) models.
Investigated the interactions between innate and adaptive immune cells mediated by TH17 cells.

Main Results:

Simulation results for TH17 models aligned with existing clinical data.
The study suggests a potential pathway involving the Dendritic Cell-IL23-TH17 axis in severe asthma development.
Identified a significant role for TH17 cells in the pathophysiology of severe asthma.

Conclusions:

The DC-IL23-TH17 axis is implicated as a causative pathway in severe asthma.
TH17 cells represent a promising new target for clinical interventions in severe asthma.
Computational modeling provides valuable insights into complex immune system interactions relevant to severe asthma.